Free Trial

Syndax Pharmaceuticals Q4 2024 Earnings Report

Syndax Pharmaceuticals logo
$12.95 -0.15 (-1.15%)
As of 03/14/2025 04:00 PM Eastern

Syndax Pharmaceuticals EPS Results

Actual EPS
-$1.10
Consensus EPS
-$0.31
Beat/Miss
Missed by -$0.79
One Year Ago EPS
N/A

Syndax Pharmaceuticals Revenue Results

Actual Revenue
$7.68 million
Expected Revenue
$86.32 million
Beat/Miss
Missed by -$78.64 million
YoY Revenue Growth
N/A

Syndax Pharmaceuticals Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Remove Ads

Syndax Pharmaceuticals Earnings Headlines

Research Analysts Issue Forecasts for SNDX FY2025 Earnings
Your Wealth is Under Attack
Have you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's coming next. But here's the truth… This is just the beginning. Trump has made it clear his tariffs are coming, and that the market will get worse before it gets better. Luckily, our FREE Presidential Transition Guide details exactly what will happen in the next 100 days, and how to protect your hard-earned savings during these times. Don't wait for the next crash to wipe you out. Act now.
What is B. Riley's Forecast for SNDX Q3 Earnings?
Brokers Set Expectations for SNDX Q1 Earnings
See More Syndax Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Syndax Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Syndax Pharmaceuticals and other key companies, straight to your email.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals (NASDAQ:SNDX), a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

View Syndax Pharmaceuticals Profile

More Earnings Resources from MarketBeat